An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma

Journal of Clinical Pathology

Volumn 61, Issue 5, 2008, Pages 652-657

  Miller, K ^a   Price, J H ^a   Dobbs, S P ^a   McClelland, R H ^a   Kennedy, K ^a   McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYTOKERATIN 7; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN ANTIBODY; PROTEIN P16; PROTEIN P53; PROTEIN P63; WT1 PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MORPHOLOGICAL TRAIT; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 43549109828     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.053793     Document Type: Article

References (32)

1. Cannistra SA. Cancer of the ovary. N Eng J Med 2004;351:2519-29.
2. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002;55:27-31.
3. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4.
4. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
5. Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int J Gynecol Pathol 2003;22:37-41.
6. Malpica A, Deavers MT, Tomos C. Interobserver and intraobserver variability of a twotier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007;31:1168-74.
7. Russell SE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004;203:617-9.
8. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004;23:97-9.
9. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-63
10. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004;44:109-15.
11. Goldstein NS, Uzieblo A. WT-1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117:541-5.
12. McCluggage WG. My thoughts on and approach to the typing of ovarian carcinomas. J Clin Pathol 2008;61:152-63.
13. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30.
14. Honkoop AH, Pinedo HM, De Jong JS, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997;107:211-8,
15. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994;73:2680-6.
16. Junker K, Thomas M, Schulmann K, et al. Regression grading of neoadjuvant non small-cell lung carcinoma treatment. Pathologe 1997;18:131-40.
17. Rouzbahman M, Serra S, Chetty R. Rectal adenocarcinoma with oncocytic features possible relationship with preoperative chemoradiotherapy. J Clin Pathol 2006;59:1039-43.
18. O'Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical analysis between low-grade and high-grade ovarian serous carcinomas. Significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high grade neoplasms. Am J Surg Pathol 2005;29:1034-41.
19. O'Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007;50:773-9.
20. Vang R. Gown AM, Farinola M, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol 2007;31:653-63.
21. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 2007;26:328-33.
22. Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue. A light-microscopic, ultrastructural and immunocytochemical study. Am J Surg Pathol 1986;10:34-47.
23. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and BER-ep4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007;31:1139-48.
24. Ordonez NJ. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol 2005;36:1163-7.
25. Yang A, Kaghad A, Wang Y, et al. p63, a p53 homolog at 3q27-29 encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
26. Liao XY, Xue WC, Shen DH, et al. p63 expression in ovarian tumours: a marker for Brenner tumours but not transitional cell carcinomas. Histopathology 2007;51:477-83.
27. Honkoop AH, Rnedo HM, De Jong JS, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997;107:211-8.
28. Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
29. Lee J, Im YH, Lee SH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/ docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 2008;61:569-77.
30. Sassen S, Schmalfeldt B, Avril N, et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 2007;38:926-34.
31. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95:681-95.
32. Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe 1983;4:135-41.